MX390201B - Nueva formulacion que comprende un derivado de bencimidazol - Google Patents

Nueva formulacion que comprende un derivado de bencimidazol

Info

Publication number
MX390201B
MX390201B MX2019007239A MX2019007239A MX390201B MX 390201 B MX390201 B MX 390201B MX 2019007239 A MX2019007239 A MX 2019007239A MX 2019007239 A MX2019007239 A MX 2019007239A MX 390201 B MX390201 B MX 390201B
Authority
MX
Mexico
Prior art keywords
benzimidazole derivative
preparation containing
preparation
novel preparation
oral administration
Prior art date
Application number
MX2019007239A
Other languages
English (en)
Other versions
MX2019007239A (es
Inventor
Chun Seon Lyu
Da Won Oh
Hyungsuk Lim
Kyungmin Shin
Su Young Park
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62710016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX390201(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of MX2019007239A publication Critical patent/MX2019007239A/es
Publication of MX390201B publication Critical patent/MX390201B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una nueva formulación que comprende un derivado de bencimidazol. La formulación para administración oral que comprende un compuesto de Fórmula 1 de acuerdo con la presente invención o una sal farmacéuticamente aceptable del mismo; y al menos un disgregante seleccionado del grupo que consiste en croscarmelosa de sodio, almidón glicolato sódico ye hidroxipropilcelulosa con bajo grado de sustitución, muestra una excelente estabilidad durante el almacenamiento y tiene un efecto en la prevención de un fenómeno de disminución en la velocidad de disolución, usándose de esta manera de forma útil como una formulación para administración oral.
MX2019007239A 2016-12-26 2017-12-26 Nueva formulacion que comprende un derivado de bencimidazol MX390201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160179334A KR101960357B1 (ko) 2016-12-26 2016-12-26 벤즈이미다졸 유도체를 포함하는 신규한 제제
PCT/KR2017/015489 WO2018124700A1 (ko) 2016-12-26 2017-12-26 벤즈이미다졸 유도체를 포함하는 신규한 제제

Publications (2)

Publication Number Publication Date
MX2019007239A MX2019007239A (es) 2019-08-16
MX390201B true MX390201B (es) 2025-03-20

Family

ID=62710016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007239A MX390201B (es) 2016-12-26 2017-12-26 Nueva formulacion que comprende un derivado de bencimidazol

Country Status (14)

Country Link
US (2) US11576898B2 (es)
EP (1) EP3560482B9 (es)
JP (1) JP6814886B2 (es)
KR (1) KR101960357B1 (es)
CN (2) CN110121333B (es)
AR (1) AR110453A1 (es)
ES (1) ES2887020T3 (es)
JO (1) JOP20170197B1 (es)
MX (1) MX390201B (es)
MY (1) MY191261A (es)
PH (1) PH12019501288A1 (es)
TW (1) TWI658841B (es)
UY (1) UY37550A (es)
WO (1) WO2018124700A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3927340T (lt) * 2019-02-18 2025-12-29 Hk Inno.N Corporation Farmacinė kompozicija, apimanti tegoprazaną, skirta gastroezofaginio refliukso ligos recidyvo profilaktikai
MX2022012848A (es) * 2020-04-13 2023-01-16 Hk Inno N Corp Composicion farmaceutica que comprende compuesto derivado de benzimidazol.
CN116507318A (zh) * 2020-10-23 2023-07-28 怡诺安有限公司 包含苯并咪唑衍生物化合物的口服崩解片剂及其制备方法
WO2024228133A1 (en) * 2023-05-02 2024-11-07 Metrochem Api Pvt Ltd Novel salts of tegoprazan and its polymorphs
KR20250178892A (ko) * 2024-06-20 2025-12-29 화일약품주식회사 테고프라잔의 신규 염 및 이의 제조방법
DE102024002434A1 (de) 2024-07-25 2026-01-29 Mercedes-Benz Group AG Modulare Einheit zur Anordnung in einer Nabe eines Fahrzeugrades mit beweglichen Aeroelementen und Rad für ein Kraftfahrzeug

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE471319T1 (de) * 2005-12-19 2010-07-15 Raqualia Pharma Inc Chromansubstituierte benzimidazole und ihre verwendung als säurepumpenhemmer
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
MY197209A (en) * 2015-06-08 2023-06-01 Raqualia Pharma Inc Uses of benzimidazole derivative for nocturnal acid breakthrough

Also Published As

Publication number Publication date
MY191261A (en) 2022-06-12
EP3560482A1 (en) 2019-10-30
CN110121333B (zh) 2023-07-04
KR20180075235A (ko) 2018-07-04
JP6814886B2 (ja) 2021-01-20
US20230277506A1 (en) 2023-09-07
CN110121333A (zh) 2019-08-13
CN116869915A (zh) 2023-10-13
WO2018124700A1 (ko) 2018-07-05
EP3560482B9 (en) 2022-04-20
BR112019013098A2 (pt) 2019-12-17
EP3560482A4 (en) 2020-08-19
MX2019007239A (es) 2019-08-16
JOP20170197A1 (ar) 2019-01-30
EP3560482B1 (en) 2021-08-18
UY37550A (es) 2018-07-31
US11576898B2 (en) 2023-02-14
ES2887020T3 (es) 2021-12-21
US20200392120A1 (en) 2020-12-17
KR101960357B1 (ko) 2019-03-20
TW201828928A (zh) 2018-08-16
PH12019501288A1 (en) 2019-12-02
AR110453A1 (es) 2019-03-27
JOP20170197B1 (ar) 2022-03-14
TWI658841B (zh) 2019-05-11
JP2020502208A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
ZA202206923B (en) New methylquinazolinone derivatives
MX2021004000A (es) Derivados de piperidina.
EP4252848A3 (en) Oxysterols and methods of use thereof
EP4609866A3 (en) Oxysterols and methods of use thereof
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MY183536A (en) Pharmaceutical compositions comprising azd9291
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
HK1255500A1 (zh) 氧固醇及其使用方法
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4